3 recruiting, 2 active not recruiting, 2 terminated, 1 completed. 4 Phase 2, 3 Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Active not recruiting 1, Terminated 1 |
| Phase 1 | 3 | Active not recruiting 2, Completed 1 |
| Not applicable | 1 | Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Primary Peritoneal Carcinosarcoma: new trials by email Literature Review of Primary Peritoneal Carcinosarcoma trials Research Report on Primary Peritoneal Carcinosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 3 | Recruiting | NRG Oncology | 880 | 2025-03-12 | 2026-08-07 |
| Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial Biopsy, Biospecimen Collection, Computed Tomography - Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Recruiting | Mayo Clinic | 78 | 2024-11-12 | 2026-10-02 |
| Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Biopsy, Biospecimen Collection, Computed Tomography - Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 38 | 2023-09-28 | 2026-09-21 |
| APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion Bevacizumab, Biopsy, Biospecimen Collection - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 60 | 2023-04-27 | 2026-03-23 |
| A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Biospecimen Collection, Computed Tomography, Echocardiography Test - Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 55 | 2020-05-07 | 2026-07-20 |
| The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors Exercise Counseling, Aerobic Exercise, Physiological Support - Ovarian Cancer, Fallopian Tube Adenocarcinoma | Not applicable | Terminated | University of Washington | 64 | 2018-12-05 | 2023-11-29 |
| MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Bevacizumab, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | Mayo Clinic | 17 | 2015-03-13 | 2025-12-11 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel - Cervical Adenocarcinoma, Cervical Adenosarcoma | Phase 1 | Completed | Mayo Clinic | 43 | 2014-02-24 | 2024-07-26 |
Ovarian Neoplasms (6) · Fallopian Tube Neoplasms (4) · Neoplasms (2) · Brenner Tumor (1)
Adnexal Diseases (6) · Endocrine Gland Neoplasms (6) · Endocrine System Diseases (6) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Genital Diseases (6) · Genital Diseases, Female (6) · Genital Neoplasms, Female (6) · Gonadal Disorders (6) · Neoplasms by Site (6) · Ovarian Diseases (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6) · Fallopian Tube Diseases (4) · Neoplasms (4)
Specimen Handling (5) · Bevacizumab (4) · Disulfides (4) · Immunoglobulin G (4) · Magnetic Resonance Spectroscopy (4) · Biopsy (3) · Doxorubicin (2) · Taxes (2) · liposomal doxorubicin (2) · pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Blood Component Removal (1) · Diphtheria Toxoid (1) · Diphtheria-Tetanus Vaccine (1)
Mayo Clinic (4) · NRG Oncology (1) · National Cancer Institute (NCI) (1) · Roswell Park Cancer Institute (1) · University of Washington (1)
United States (8) · Japan (1) · Puerto Rico (1)
Matthew S. Block, MD, PhD (2) · Emese Zsiros (1) · Evanthia Galanis, M.D. (1) · Kathryn Pennington (1) · Matthew S. Block, M.D., Ph.D. (1) · Rachel N Grisham (1) · Ying Liu (1)
R01CA267690 (1), R01CA276313 (1), R21CA215662 (1), U10CA180868 (1), UM1CA186691 (1)